Chemistry:TS-121
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Other names | TS-1211 |
| Routes of administration | By mouth |
TS-121 (THY1773) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[1][2][3] As of May 2017, it is in phase II clinical trials for this indication.[1][2][4]
See also
- ABT-436
- Balovaptan
- List of investigational antidepressants
- Nelivaptan
- SRX-246
References
- ↑ 1.0 1.1 "TS 121 -". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800041804.
- ↑ 2.0 2.1 "New Drug Pipeline - Taisho Pharmaceutical Holdings". http://www.taisho-holdings.co.jp/en/ir/finance/development/.
- ↑ "Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study". Journal of Psychiatric Research 128: 43–51. September 2020. doi:10.1016/j.jpsychires.2020.05.017. PMID 32521250.
- ↑ "Prediction of a clinically effective dose of THY1773, a novel V1B receptor antagonist, based on preclinical data". Biopharmaceutics & Drug Disposition 42 (5): 204–217. May 2021. doi:10.1002/bdd.2273. PMID 33734452.
External links
- Clinical trial number NCT03093025 for "A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder" at ClinicalTrials.gov
 |
